A death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at Xinhua Hospital in Shanghai has reopened debate over how regulators oversee personalized, first-in-human gene editing. The case has intensified scrutiny around risk-benefit thresholds, monitoring, and governance for early clinical use of editing platforms.